JP2021502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502984A5 JP2021502984A5 JP2020526504A JP2020526504A JP2021502984A5 JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025269754A JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201762.6 | 2017-11-15 | ||
| EP17201762 | 2017-11-15 | ||
| EP18174634 | 2018-05-28 | ||
| EP18174634.8 | 2018-05-28 | ||
| PCT/EP2018/081296 WO2019096874A1 (en) | 2017-11-15 | 2018-11-15 | Factor x binders enhancing fx activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025269754A Division JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502984A JP2021502984A (ja) | 2021-02-04 |
| JP2021502984A5 true JP2021502984A5 (enExample) | 2021-12-02 |
Family
ID=64426877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526504A Pending JP2021502984A (ja) | 2017-11-15 | 2018-11-15 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| JP2025269754A Pending JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025269754A Pending JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11787874B2 (enExample) |
| EP (2) | EP4667496A2 (enExample) |
| JP (2) | JP2021502984A (enExample) |
| CN (2) | CN111386285B (enExample) |
| ES (1) | ES3050257T3 (enExample) |
| MA (1) | MA50893A (enExample) |
| WO (1) | WO2019096874A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US11787874B2 (en) * | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| ES2901683T3 (es) | 2018-12-21 | 2022-03-23 | Kymab Ltd | Anticuerpo biespecífico FIXAXFX con cadena ligera común |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| EP4314075A4 (en) * | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CD3 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| WO2023225035A2 (en) * | 2022-05-16 | 2023-11-23 | Artisan Development Labs, Inc. | Compositions and methods for engineering cells |
| KR102749341B1 (ko) * | 2022-07-08 | 2025-01-06 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
| AU2023303873A1 (en) * | 2022-07-08 | 2025-01-02 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
| CN115960227A (zh) * | 2022-11-08 | 2023-04-14 | 河南赛诺特生物技术有限公司 | 一种抗人msh2的单克隆抗体及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| WO1995001571A1 (en) | 1993-07-01 | 1995-01-12 | Baxter Diagnostics Inc. | Process for the preparation of factor x depleted plasma |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2004041862A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EP2824183B1 (en) | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| BRPI0816837B1 (pt) | 2007-09-28 | 2022-10-18 | Portola Pharmaceuticals, Inc | Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| TWI831106B (zh) * | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| AU2017303205B2 (en) | 2016-07-29 | 2024-08-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| IL265144B2 (en) | 2016-09-06 | 2024-10-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| JP7227146B2 (ja) | 2016-11-23 | 2023-02-21 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体 |
| US11787874B2 (en) * | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
-
2018
- 2018-11-15 US US16/764,124 patent/US11787874B2/en active Active
- 2018-11-15 ES ES18807239T patent/ES3050257T3/es active Active
- 2018-11-15 EP EP25187342.8A patent/EP4667496A2/en active Pending
- 2018-11-15 JP JP2020526504A patent/JP2021502984A/ja active Pending
- 2018-11-15 MA MA050893A patent/MA50893A/fr unknown
- 2018-11-15 WO PCT/EP2018/081296 patent/WO2019096874A1/en not_active Ceased
- 2018-11-15 CN CN201880073999.9A patent/CN111386285B/zh active Active
- 2018-11-15 EP EP18807239.1A patent/EP3710486B1/en active Active
- 2018-11-15 CN CN202411097090.0A patent/CN118745229A/zh active Pending
-
2023
- 2023-09-06 US US18/242,868 patent/US20230416404A1/en active Pending
-
2025
- 2025-12-19 JP JP2025269754A patent/JP2026040534A/ja active Pending